Proposed experiment from debate on TDP-43 undergoes liquid-liquid phase separation that becomes pathological. Small

🧫 Experiment Protocol FalsificationNeurodegenerationTDPcell_lineproposed

# Proposed experiment from debate on TDP-43 undergoes liquid-liquid phase separation that becomes pathological. Small ## Background and Rationale This falsification study critically examines the selectivity of peptide mimetics designed to disrupt pathological TDP-43 liquid-liquid phase separation while preserving physiological TDP-43 functions. TDP-43 proteinopathies are characterized by aberrant phase separation leading to cytoplasmic aggregation, but physiological TDP-43 also undergoes reversible phase separation for normal RNA processing. The experiment employs a panel of peptide mimetics targeting different TDP-43 domains (LCD, RRM1/2, NTD) and tests their effects on both pathological aggregation (induced by oxidative stress, ALS mutations, or prolonged expression) and physiological functions (mRNA splicing, stress granule dynamics, nuclear-cytoplasmic shuttling). Cell-based assays will utilize HEK293T or neuroblastoma cells expressing wild-type or mutant TDP-43 constructs, with live-cell imaging to monitor phase separation dynamics and biochemical assays to assess RNA-binding activity. The key innovation lies in developing concentration-dependent response curves to identify therapeutic windows where peptides selectively inhibit pathological aggregation without disrupting essential TDP-43 functions. This approach addresses a critical gap in current therapeutic strategies by testing whether it's possible to pharmacologically distinguish between beneficial and harmful TDP-43 phase transitions. This experiment directly tests predictions arising from the following hypotheses: - **Low Complexity Domain Cross-Linking Inhibition** - **Glycine-Rich Domain Competitive Inhibition** - **Cryptic Exon Silencing Restoration** - **Cross-Seeding Prevention Strategy** - **R-Loop Resolution Enhancement Therapy** ## Experimental Protocol **Phase 1: Cell Culture Preparation (Days 1-3)** • Culture HEK293T and SH-SY5Y neuroblastoma cell lines in DMEM with 10% FBS • Transfect cells with plasmids encoding wild-type TDP-43, pathological mutants (A315T, M337V), and fluorescently-tagged constructs • Prepare control cells with empty vector and mock transfection • Achieve 70-80% confluency in 96-well plates (n=8 wells per condition) **Phase 2: Peptide Mimetic Characterization (Days 4-6)** • Synthesize peptide mimetics targeting TDP-43 low-complexity domain interactions • Prepare serial dilutions from 0.1 μM to 100 μM in serum-free medium • Perform dose-response curves using alamarBlue viability assay at 24h, 48h, 72h timepoints • Calculate IC50 values and establish non-toxic concentration ranges **Phase 3: Phase Separation Selectivity Testing (Days 7-10)** • Induce physiological TDP-43 condensates using 5% PEG-8000 treatment • Induce pathological aggregates via oxidative stress (200 μM H2O2) or heat shock (42°C, 2h) • Apply peptide mimetics at 0.5×, 1×, 2×, and 5× IC20 concentrations • Perform live-cell fluorescence microscopy every 2h for 24h • Quantify condensate size, number, and dynamics using ImageJ analysis **Phase 4: Functional Splicing Analysis (Days 11-14)** • Extract total RNA at 6h, 12h, and 24h post-treatment timepoints • Perform RT-qPCR analysis of known TDP-43 splicing targets (CFTR exon 9, SORT1, FTD-associated genes) • Conduct RNA-seq analysis on samples from optimal peptide concentration • Validate splicing changes using minigene reporter assays in triplicate **Phase 5: Mechanistic Validation (Days 15-18)** • Perform co-immunoprecipitation assays to assess peptide effects on TDP-43 protein-protein interactions • Conduct FRAP analysis to measure condensate dynamics and recovery kinetics • Use proximity ligation assays to quantify pathological vs. physiological TDP-43 complexes • Perform western blot analysis for TDP-43 phosphorylation and cleavage products ## Expected Outcomes 1. Peptide mimetics will demonstrate 3-5 fold selectivity for disrupting pathological TDP-43 aggregates over physiological condensates, as measured by fluorescence recovery half-times (pathological: <30s recovery vs. physiological: >120s recovery) 2. Minimum effective concentration for aggregate disruption will be 2-10 μM, at least 5-fold below cytotoxicity threshold (IC50 >50 μM) based on alamarBlue viability assays 3. Treatment will preserve >85% of normal TDP-43-dependent splicing events, with <15% change in splicing efficiency for known physiological targets compared to vehicle controls 4. Pathological TDP-43 condensate number will decrease by >60% while maintaining <20% reduction in physiological condensate formation at optimal peptide concentrations 5. Co-immunoprecipitation will show >50% reduction in pathological TDP-43-protein interactions while preserving >80% of normal RNA-binding interactions 6. FRAP analysis will demonstrate restored dynamics in pathological condensates (recovery half-time reduced from >300s to <60s) without significantly altering physiological condensate kinetics ## Success Criteria • Achieve statistical significance (p<0.05) for selective disruption of pathological vs. physiological TDP-43 interactions with effect size >0.8 • Establish therapeutic window with minimum 5-fold separation between effective concentration and cytotoxicity (IC50/EC50 ratio >5) • Demonstrate preservation of ≥80% normal splicing function with <20% change in physiological TDP-43 targets (p>0.05 vs. controls) • Obtain minimum n=6 biological replicates per condition with technical triplicates, achieving >80% experimental success rate • Validate selectivity using at least 3 independent assays (microscopy, biochemical, functional) with consistent results (correlation coefficient >0.7) • Reproduce key findings in both HEK293T and SH-SY5Y cell lines to demonstrate model system independence

Source: debate_extraction

🧫 Experiment Extras

📊 Evidence Profile

0 supporting 0 contradicting 0 neutral

🌍 Provenance Graph 1 nodes, 0 edges

No provenance edges found